Planning safer electron FLASH radiation treatments
Treatment Planning System for Electron FLASH radiation therapy
This project builds computer tools to help doctors plan electron FLASH radiation that may better protect healthy tissue for people needing high‑dose radiotherapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11319868 on NIH RePORTER |
What this research studies
From a patient perspective, researchers are creating and testing a treatment‑planning system that models how ultra‑high dose rate electron FLASH radiation deposits dose in larger, deeper bodies. They will use advanced simulations, imaging data, and comparisons with animal models to understand and reduce dose inhomogeneities. The team plans to adapt the planning tools for use at clinical radiation centers so plans for humans and large animals can be generated more reliably. Their work aims to make FLASH treatments safer and more predictable before wider human testing.
Who could benefit from this research
Good fit: Ideal future candidates would be patients with deep or radioresistant tumors who might qualify for clinical FLASH radiation trials at specialized centers.
Not a fit: People whose care does not involve high‑dose radiotherapy, or who are ineligible for radiation, are unlikely to benefit directly from this planning work.
Why it matters
Potential benefit: If successful, this could let doctors give very high‑dose radiation while reducing harm to normal organs, potentially enabling treatment of tumors that are otherwise too risky to irradiate.
How similar studies have performed: Early small‑animal studies have reported reduced normal tissue damage with FLASH and a few large‑animal or early human efforts have started, but clinical benefit is still not proven.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Zhang, Rongxiao — University of Missouri-Columbia
- Study coordinator: Zhang, Rongxiao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.